OriGene Technologies, Inc.
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 
Home shRNA All PLAGL1 shRNA/siRNA

PLAGL1 (Gene ID 5325) Human shRNA

divider

To view the shRNA sequence, please register your email:
Email:
Register To View
Specifications Citations Related Products Product Documents
SKU Description Vector Price Availability*  
TG310381
  • PLAGL1 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector (Gene ID = 5325). 5µg purified plasmid DNA per construct
  • Non-effective 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.



650 2 Weeks
Add to Shopping Cart
spacer
Also for PLAGL1 (Locus ID 5325)
cDNA Clone qPCR Master Mix Primer Pair siRNA Antibody Service
spacer
Register To View Sequence

Reference Data
RefSeq: BD135162NM_001080951NM_001080952NM_001080953NM_001080954NM_001080955NM_001080956
NM_001289037NM_001289038NM_001289039NM_001289040NM_001289041NM_001289042NM_001289043NM_001289044NM_001289045NM_001289046NM_001289047NM_001289048NM_001289049NM_002656NM_006718
Synonyms: LOT1; ZAC; ZAC1
Summary: This gene encodes a C2H2 zinc finger protein with transactivation and DNA-binding activities. It has been shown to have anti-proliferative properties, and thus thought to function as a tumor suppressor. In addition, overexpression of this gene during fetal development is believed to underlie the rare disorder, transient neonatal diabetes mellitus (TNDM). This gene is imprinted, with preferential expression of the paternal allele in many tissues, however, biallelic expression has been noted in peripheral blood leucocytes. A recent study reports that tissue-specific imprinting results from variable utilization of monoallelic and biallelic promoters. Many transcript variants differing in the 5' UTR and encoding two different isoforms, have been found for this gene. [provided by RefSeq, Oct 2010].
shRNA Design:
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
Performance Guranteed:
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

 


* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping

 

pattern
Inc 5000 Healthcare Company Copyright © 2014 OriGene Technologies, Inc. All Rights Reserved. Legal Notices.
9620 Medical Center Dr., Suite 200, Rockville, MD 20850 • 1.888.267.4436

Reproduction of any materials from this website is strictly forbidden without permission.

All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title